Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS.

Hongjiang LiuChun LiHui ShiYixue GuoYundi TangChen ChenZhen ZhaoClaire K HoySrilakshmi YalavarthiGabriel Figueroa-Parra Ali Duarte GarciaYu ZuoZhanguo LiJason S KnightJianping Guo

Published in: Rheumatology (Oxford, England) (2022)

Our study provides first evidence that LILRA3 is aberrantly expressed in APS, especially in patients with tAPS. Serum LILRA3 correlated with MPO-DNA complexes, and the two indices were consistently decreased in tAPS patients after treatment. LILRA3 may play a role in thrombosis of APS and may serve as a biomarker and/or therapeutic target in tAPS.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
cell free
circulating tumor
patient reported